Compare CORT & HRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | HRB |
|---|---|---|
| Founded | 1998 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 4.9B |
| IPO Year | 2001 | 1994 |
| Metric | CORT | HRB |
|---|---|---|
| Price | $110.60 | $53.34 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 5 | 2 |
| Target Price | ★ $96.50 | $41.00 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.34% |
| EPS Growth | N/A | ★ 6.55 |
| EPS | 0.09 | ★ 3.38 |
| Revenue | $761,407,000.00 | ★ $3,159,931,000.00 |
| Revenue This Year | $26.08 | $4.39 |
| Revenue Next Year | $26.98 | $3.21 |
| P/E Ratio | $1,246.44 | ★ $16.03 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $28.16 |
| 52 Week High | $122.21 | $58.67 |
| Indicator | CORT | HRB |
|---|---|---|
| Relative Strength Index (RSI) | 62.28 | 75.45 |
| Support Level | $76.41 | $41.90 |
| Resistance Level | $122.21 | N/A |
| Average True Range (ATR) | 5.00 | 2.25 |
| MACD | -0.03 | 0.73 |
| Stochastic Oscillator | 65.76 | 68.99 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
H&R Block Inc provides income tax return preparation services, digital do-it-yourself tax solutions, and other services related to income tax preparation to the general public in the United States, Canada, and Australia. The company mainly prepares tax returns for customers within the United States through its company-owned offices, franchise locations, and online tax software. The vast majority of H&R Block's offices are located in the U.S. The company derives the majority of its total revenue from the U.S. assisted tax preparation fees. Revenue from franchise and product royalties and digital do-it-yourself tax solutions is also relatively.